Abstract
Objectives Mammographic density is associated with increased risk of developing breast cancer. Automated estimation of density in women below normal screening age would enable earlier risk stratification. We are piloting the use of low dose mammograms combined with models that can make accurate mammographic density estimates.
Methods Three models were trained on a joint set (107,619) of standard dose mammograms with associated density scores and their simulated low dose counterparts such that the models made predictions on standard and low dose mammograms. A second set of models was trained separately on the standard and simulated low dose mammograms. All models were tested on a held-out set from the training data and an independent dataset with 294 pairs of standard and real low dose mammograms.
Results The root mean squared errors (RMSE) between the model predictions and density scores on standard and simulated low dose images were 8.26 (8.16-8.36) and 8.27 (8.17-8.38) respectively. The RMSE between predictions on standard and simulated low dose images for the jointly trained models was 1.91 (1.88-1.96). The RMSE of the predictions on the real low dose images compared to the standard dose images is 3.79 (2.75-4.99).
Conclusions Deep learning models make density predictions on low dose images with similar quality as on standard dose images. Such automated analysis of low dose mammograms could contribute to accurate breast cancer risk estimation in younger women enabling stratification for further monitoring and preventative therapy.
Advances in knowledge Mammographic density can be estimated in low dose mammograms with similar quality to standard dose mammograms.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
ISRCTN55983830
Funding Statement
The ALDRAM study was funded by the Medical Research Council (UK).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics approval for the PROCAS study was through the North Manchester Research Ethics Committee (09/H1008/81). Informed consent was obtained from all participants on entry to the PROCAS study. Ethics approval for the ALDRAM study was granted on 12/02/2019 by the North West - Preston Research Ethics Committee (Barlow House, 3rd Floor, 4 Minshull Street, Manchester M1 3DZ; +44 (0)2071048234; preston.rec{at}hra.nhs.uk), ref: 19/NW/0037
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Data is not currently available to researchers outside of the University of Manchester.
